inner-banner-bg

Advances in Hematology and Oncology Research(AHOR)

ISSN: 2692-5516 | DOI: 10.33140/AHOR

Impact Factor: 1.2

Outcomes of Brentuximab Vedotin with or without Bendamustine and Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma: An Early Experience from Patient Access Programme in India

Citation

Jyothi Goutham, Samrudhi Joshi, Shekar Patil, Satheesh Chiradoni Thungappa, Ravi Thippeswamy, Shashidha-ra HP, Nishit Ojha, Amey C Panchal, Yesheswini N Naik, Jayantha Balawardane and Sachin Suresh Jadhav

Goutham, J., Joshi, S., Patil, S., Thungappa, S. C., Thippeswamy, R., et al. (2024). Outcomes of Brentuximab Vedotin with or without Bendamustine and Nivolumab in Relapsed or Refractory Hodgkinâ??s Lymphoma: An Early Experience from Patient Access Programme in India. Adv Hema Onco Res, 7(1), 01-07.

Abstract PDF